Xeris Pharmaceuticals Hosts Analyst and Investor Day

Xeris Pharmaceuticals ( (XERS) ) has shared an update.

Xeris Pharmaceuticals announced its first Analyst and Investor Day scheduled for June 3, 2025, in New York City, where senior management will discuss the company’s growth strategy and financial outlook. The event aims to highlight the potential of products like Recorlev® and XP-8121, emphasizing their expected impact on revenue growth and the treatment landscape for conditions such as hypothyroidism, potentially affecting stakeholders by demonstrating the company’s commitment to long-term value creation.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.

Spark’s Take on XERS Stock

According to Spark, TipRanks’ AI Analyst, XERS is a Neutral.

Xeris Pharmaceuticals scores a 63, attributed to robust revenue growth and positive earnings call sentiment. Technical indicators show upward momentum, further supporting the stock’s prospects. However, profitability challenges, high leverage, and valuation concerns weigh on the overall score, highlighting the need for improved financial stability and investor confidence.

To see Spark’s full report on XERS stock, click here.

More about Xeris Pharmaceuticals

Xeris Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing innovative therapies that address serious, unmet medical needs. The company is particularly involved in creating products for conditions such as hypothyroidism and other endocrine disorders, with a market focus on improving patient outcomes through novel treatments.

Average Trading Volume: 3,151,458

Technical Sentiment Signal: Buy

Current Market Cap: $808.8M

Learn more about XERS stock on TipRanks’ Stock Analysis page.